A Retrospective Analysis of the First 41 mCRPC Patients with Bone Pain Treated with Radium-223 at the National Institute of Oncology in Hungary von Küronya, Zs, Sinkovics, I, Ágoston, P, Bíró, K, Bodrogi, I, Böde, I, Dank, M, Gyergyay, F, Vajdics, T, Kolonics, Zs, Nagyiványi, K, Rúzsa, Á, Géczi, L

Volltext

Characteristics and Risk Factors of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients Detected by Distorsion Product Otoacoustic Emission von Biro, K., Noszek, L., Prekopp, P., Nagyiványi, K., Géczi, L., Gaudi, I., Bodrogi, I.

Volltext

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma von Motzer, Robert J, Tannir, Nizar M, McDermott, David F, Arén Frontera, Osvaldo, Melichar, Bohuslav, Choueiri, Toni K, Plimack, Elizabeth R, Barthélémy, Philippe, Porta, Camillo, George, Saby, Powles, Thomas, Donskov, Frede, Neiman, Victoria, Kollmannsberger, Christian K, Salman, Pamela, Gurney, Howard, Hawkins, Robert, Ravaud, Alain, Grimm, Marc-Oliver, Bracarda, Sergio, Barrios, Carlos H, Tomita, Yoshihiko, Castellano, Daniel, Rini, Brian I, Chen, Allen C, Mekan, Sabeen, McHenry, M. Brent, Wind-Rotolo, Megan, Doan, Justin, Sharma, Padmanee, Hammers, Hans J, Escudier, Bernard

Volltext

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma von Choueiri, Toni K, Escudier, Bernard, Powles, Thomas, Mainwaring, Paul N, Rini, Brian I, Donskov, Frede, Hammers, Hans, Hutson, Thomas E, Lee, Jae-Lyun, Peltola, Katriina, Roth, Bruce J, Bjarnason, Georg A, Géczi, Lajos, Keam, Bhumsuk, Maroto, Pablo, Heng, Daniel Y.C, Schmidinger, Manuela, Kantoff, Philip W, Borgman-Hagey, Anne, Hessel, Colin, Scheffold, Christian, Schwab, Gisela M, Tannir, Nizar M, Motzer, Robert J

Volltext

Somatic mutations of KIT in familial testicular germ cell tumours von Rapley, E A, Hockley, S, Warren, W, Johnson, L, Huddart, R, Crockford, G, Forman, D, Leahy, M G, Oliver, D T, Tucker, K, Friedlander, M, Phillips, K-A, Hogg, D, Jewett, M A S, Lohynska, R, Daugaard, G, Richard, S, Heidenreich, A, Geczi, L, Bodrogi, I, Olah, E, Ormiston, W J, Daly, P A, Looijenga, L H J, Guilford, P, Aass, N, Fosså, S D, Heimdal, K, Tjulandin, S A, Liubchenko, L, Stoll, H, Weber, W, Einhorn, L, Weber, B L, McMaster, M, Greene, M H, Bishop, D T, Easton, D, Stratton, M R

Volltext

1815P Emergent circulating tumor DNA (ctDNA) variants and ctDNA burden dynamics with potential associations with talazoparib antitumor activity in TALAPRO-1 von Castro, E., Laird, D., Dorff, T., Zhao, S., van Oort, I.M., Gasparro, D., Calabro', F., Pignata, S., Geczi, L., Barthelemy, P., Kilari, D., Hopkins, J.F., Chen, H-C., Healy, C.G., Chelliserry, J., Scagliotti, G., de Bono, J.S., Mehra, N., Fizazi, K.

Volltext

Steroid switch: Reversal of resistance to abirateron acetate (AA) and prednisolone (P) combination in metastatic castration-resistant prostate cancer (mCRPC) patients von Gyergyay, F., Budai, B., Biro, K., Küronya, Z., Nagyivanyi, K., Geczi, L.

Volltext

1368P TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm) – Exploration of tumor genetics asso... von de Bono, J.S., Castro Marcos, E., Laird, D.A., Fizazi, K., Dorff, T., Zhao, S., van Oort, I.M., Gasparro, D., Calabrò, F., Pignata, S., Geczi, L., Barthelemy, P., Kilari, D., Hopkins, J.F., Chen, H-C., Healy, C.G., Chelliserry, J., Scagliotti, G.V., Mehra, N.

Volltext

912PD - Results of the phase II TRAXAR study: A randomized phase II trial of axitinib and TRC105 (TRAX) versus axitinib (AX) alone in patients with advanced or metastatic renal cel... von Choueiri, T.K., Kocsis, J., Pachynski, R.K., Poprach, A., Deshazo, M., Zakharia, Y., Lara, P.N., Pal, S.K., Geczi, L., Ho, T.H., Mangel, L., Redman, B., Ryan, C.W., Olencki, T., Simpson, B.E., Adams, B., Robertson, L., Darif, M., Theuer, C., Agarwal, N.

Volltext

Results of the phase II TRAXAR study: A randomized phase II trial of axitinib and TRC105 (TRAX) versus axitinib (AX) alone in patients with advanced or metastatic renal cell carcin... von Choueiri, T.K., Kocsis, J., Pachynski, R.K., Poprach, A., Deshazo, M., Zakharia, Y., Lara, P.N., Pal, S.K., Geczi, L., Ho, T.H., Mangel, L., Redman, B., Ryan, C.W., Olencki, T., Simpson, B.E., Adams, B., Robertson, L., Darif, M., Theuer, C., Agarwal, N.

Volltext

LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361 von Alva, A., Csőszi, T., Ozguroglu, M., Matsubara, N., Geczi, L., Cheng, S.Y-S., Fradet, Y., Oudard, S., Vulsteke, C., Morales Barrera, R., Fléchon, A., Gunduz, S., Loriot, Y., Rodriguez-Vida, A., Mamtani, R., Yu, E.Y., Nam, K., Imai, K., Moreno, B.H., Powles, T.B.

Volltext

Incidence of osteonecrosis of the jaw (ONJ) in metastatic renal cell cancer patients (mRCC) treated with zoledronic acid (ZA) von Gyergyay, Fruzsina, Nagyivanyi, Krisztian, Biro, Krisztina, Kuronya, Zsofia, Nemeth, Hajnalka, Geczi, Lajos

Volltext

912PDResults of the phase II TRAXAR study: A randomized phase II trial of axitinib and TRC105 (TRAX) versus axitinib (AX) alone in patients with advanced or metastatic renal cell c... von Choueiri, T K, Kocsis, J, Pachynski, R K, Poprach, A, Deshazo, M, Zakharia, Y, Lara, P N, Pal, S K, Geczi, L, Ho, T H, Mangel, L, Redman, B, Ryan, C W, Olencki, T, Simpson, B E, Adams, B, Robertson, L, Darif, M, Theuer, C, Agarwal, N

Volltext

Pembrolizumab ± chemotherapy versus chemotherapy in advanced urothelial cancer: Phase 3 KEYNOTE-361 trial von Powles, T., Gschwend, J.E., Loriot, Y., Bellmunt, J., Geczi, L., Vulsteke, C., Abdelsalam, M., Gafanov, R., Bae, W.K., Revesz, J., Yamamoto, Y., Anido, U., Su, W-P., Fleming, M., Markus, M., Feng, D., Poehlein, C., Alva, A.

Volltext

Three-Year Results of the First Educational and Early Detection Program for Testicular Cancer in Hungary von Géczi, Lajos, Gomez, Frederic, Horváth, Zsolt, Bak, Mihály, Kisbenedek, László, Bodrogi, István

Volltext

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer von Fizazi, Karim, Tran, NamPhuong, Fein, Luis, Matsubara, Nobuaki, Rodriguez-Antolin, Alfredo, Alekseev, Boris Y, Özgüroğlu, Mustafa, Ye, Dingwei, Feyerabend, Susan, Protheroe, Andrew, De Porre, Peter, Kheoh, Thian, Park, Youn C, Todd, Mary B, Chi, Kim N

Volltext

Expression of bcl-2 in testicular carcinoma : Correlation with tumor progression and MDR1/Pgp von EID, H, GULYAS, M, GECZI, L, BODROGI, I, INSTITORIS, E, BAK, M

Volltext

Influence of hMLH1 Methylation, Mismatch Repair Deficiency and Microsatellite Instability on Chemoresistance of Testicular Germ-cell Tumors von OLASZ, Judit, MANDOKY, Laszlo, GECZI, Lajos, BODROGI, Istvan, CSUKA, Orsolya, BAK, Mihaly

Volltext

Do metallothioneins affect the response to treatment in testis cancers? von EID, H, GECZI, L, BODROGI, I, INSTITORIS, E, BAK, M

Volltext

Sunitinib (2 weeks on/1 week off schedule) in metastatic renal cell cancer patients. Progression free and overall survival von Gyergyay, F., Budai, B., Nagyivanyi, K., Biró, K., Géczi, L.

Volltext